Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotechs Brace to Battle a Deadly GI Bacterium

This article was originally published in Start Up

Executive Summary

C. difficile is the number one cause of infectious diahrrea in the developed world. Long thought to be a nuisance, the infections are turning deadly, and a spate of outbreaks has occurred at hospitals in the US, Canada, and Europe. Biotechs are racing to develop new therapeutics to combat the killer bug.
Advertisement

Related Content

Optimer Looks To Partner C. Diff Candidate After Trial Success
Optimer Looks To Partner C. Diff Candidate After Trial Success
Optimer Rides High After OPT-80 C. Diff Trial Success
Optimer Rides High After OPT-80 C. Diff Trial Success
ViroPharma's Second Act: First a Tough One to Follow
ViroPharma's Second Act: First a Tough One to Follow

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091030

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel